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Ab s t r Ac t
Objective: Elevation of serum liver transaminase is common during dengue infection. A group of dengue patients was studied to determine 
the relationship between the elevation of liver transaminases in dengue fever (DF) and dengue hemorrhagic fever (DHF). Methodology: This 
study was conducted to assess the predictive value of liver enzymes for DHF. During the dengue epidemic of 2017, all data pertaining to 
601 dengue patients were collected in a systematic manner for purposes of conducting an analysis on the predictive value of serum levels 
of liver transaminase for DHF. Six hundred one patients were categorized into DF and DHF, according to the World Health Organization 2009 
Dengue Management Guidelines. The data were collected retrospectively. Results: There were significant differences between aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels among DF and DHF patients, not only on day 5 of the critical phase but also 
during the acute febrile phase. The area under the ROC curve at the acute febrile phase for AST was 0.7, but in ALT, it was 0.6. However, the 
area under the ROC curve was 0.70, which indicates that AST at the acute febrile phase is a good indicator of the leaking tendency. According 
to the coordinate points of the curve, leaking can be predicted with a sensitivity of 72% and a specificity of 60% at an AST value of 59.5. 
Conclusion: The AST value of 59.5 at the acute febrile phase can be used to predict DHF. However, patients who have significantly elevated 
transaminase levels during the acute febrile phase have a higher tendency to develop DHF.
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In t r o d u c t I o n
Dengue fever (DF) is a rapidly spreading disease in tropical and 
subtropical countries, including Sri Lanka, as it has had a huge 
impact on public health.[1-4] It is a mosquito-borne RNA viral disease 
that belongs to the genus of Flavivirus and family of Flaviviridae.[5-7] 
Various serotypes of the dengue virus are transmitted to humans 
through the bites of infected Aedes mosquitoes, principally Aedes 
aegypti; others are Aedes albopictus and Aedes polynesiensis.[5-9] 
According to the data from the Epidemiology Unit of the Ministry 
of Health, Sri Lanka, during the first 8 months of the year 2017, 
125387 suspected dengue cases have been reported, compared 
to last year (2016) it is more than twice the amount (55, 150).[1-4]
Dengue is a clinical syndrome which has been mainly 
classified into symptomatic and asymptomatic disease while the 
symptomatic disease is classified into undifferentiated fever, DF, 
dengue hemorrhagic fever (DHF), and expanded dengue syndrome 
which is very rare.[5,10-14]
During the Dengue epidemic of 2017, our hospital had to manage 
a large number of dengue patients and this was a huge burden for our 
country because it required a lot of financial support as well as human 
resources. Our effort in this study is to identify the DHF patients 
among dengue patients in the acute febrile phase because they can 
be given the best care while anticipating DHF and its complications. 
On the other hand, this will limit the hospital admissions as almost all 
DF patients can be managed in a home set up like any other febrile 
viral disease. That will ultimately improve the outcome of DF and DHF 
patients and thereby reduce the burden on our country.
Aspartate Aminotransferase (AST) and Alanine 
Aminotransferase (ALT)
AST is a mitochondrial and cytoplasmic enzyme, while ALT is a 
cytoplasmic enzyme. AST is found not only in the liver but also 
1Department of Medicine, University of Peradeniya, Sri Lanka, 
2Department of Community Medicine, University of Peradeniya, 
Sri Lanka
Corresponding Author: Udaya Ralapanawa, Department of Medicine, 
University of Peradeniya, Sri Lanka. E-mail: udayapralapanawa@yahoo.com
How to cite this article: Ralapanawa U, Gunarathne M, Tennakoon S, 
Alawaththegama ATM. Liver Transaminases as a Predictor of Dengue 
Hemorrhagic Fever. Asian Pac. J. Health Sci., 2020; 7(4):35-38
Source of support: Nil
Conflicts of interest: None
Received: 20/06/2020 Revised: 25/07/2020 Accepted: 28/08/2020
in the heart, skeletal muscle, and erythrocytes, whereas the main 
source of ALT is the liver. Therefore, the rising of AST could be 
multifactorial and could also be associated with complications of 
dengue such as acute liver failure, myocarditis, and myositis.[15-17] 
However, the liver remains the main source of AST and ALT. The 
involvement of the liver in DF is a commonly observable spectrum 
condition which varies from the mild elevation of liver 
transaminases to acute liver failure with or without fatal outcomes. 
It has been reported that 3 of 270 patients in Taiwan and 5 out of 644 
patients in Vietnam had developed liver failure.[17-19] Histological 
patterns of autopsy specimens of the liver have described 
that dengue can affect the liver in many ways. Microvesicular 
steatosis, hepatocellular necrosis, apoptosis induced councilman 
bodies, inflammatory cell infiltration, Kupffer cell hyperplasia 
are those.[15,20,21] Dengue associated acute liver failure has a high 
mortality due to complications such as encephalopathy, severe 
bleeding, renal failure, and metabolic acidosis.[18,22,23] Patients who 
entered the leaking phase can go into hypovolemia and shock, 
causing prolonged hypoxia in hepatocytes. However, without 
leaking/shock, also liver can be affected by direct virus invasion 
and dysregulated host immune response.[20,22-36]
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During dengue infection, the elevation of levels of liver 
transaminase is a common condition. Here, we studied a group 
of dengue patients who developed DF and DHF to find out the 
relationship between the degree of elevation of levels of liver 
transaminase and the severity of the DF to determine whether the 
occurrence of DHF can be predicted at the acute febrile phase.
MAt e r I A l s A n d Me t h o d s
This study was conducted to assess the predictive value of 
liver enzymes for DHF. During the Dengue epidemic of 2017, 
all data pertaining to 601 dengue patients were collected in a 
systematic manner for purposes of conducting an analysis on 
the predictive value of serum levels of liver transaminase (AST 
and ALT) for DHF. For the purpose of the current study, patients 
were selected following application of inclusion and exclusion 
criteria; inclusion criteria were all patients presenting with 
confirmed dengue infection through NS1 antigen test and IgM 
and IgG antibody tests and exclusion criteria were conditions 
that would elevate liver transaminases; history of chronic liver cell 
disease, long-term alcohol usage, pregnancy, and chronic renal 
disease; and all patients were given only paracetamol within the 
correct therapeutic level. Furthermore, patients who developed 
complications of dengue infection such as acute liver failure, 
myocarditis, and bleeding were also excluded from the analysis. 
It should be noted that patients who entered DHF were stable as 
none of them progressed into severe dengue stage like dengue 
shock syndrome. The subjects were classified into DF and DHF, 
according to the world health organization Dengue Management 
Guideline, which was published in 2009.[1] Subjects were included 
in the study following ethical clearance and written informed 
consent. Data were collected retrospectively from bed head tickets 
and through routine investigation reports which were carried out 
during hospital stay. A datasheet was used to collect data for the 
variables of AST and ALT.
Data were analyzed using the IDM-SPSS version 16 statistical 
package. Monovariate analysis was used to describe the study 
sample. Student’s t-test was used to explore differences between 
mean transaminase levels within the acute phase and the critical 
phase. A ROC curve was fitted and sensitivity and specificity were 
calculated of the liver transaminases in predicting progress in to 
the critical stage.
re s u lts
A total of 601 cases were included in the current analysis. All cases 
were in the acute febrile phase of dengue illness at the time of 
recruitment. Approximately 354 ALT tests were carried out and 
134 did not progress to DHF, whereas the rest, 220, had progressed 
to DHF in that total. Mean ALT values for DF and DHF were 57.7 
and 86.3, respectively, showing that significantly higher mean 
ALT value for DHF than DF with the P-value of 0.003. AST tests 
were carried out for 351 patients showed that 66.5 mean value 
for 134 DF and 108.9 mean value for 217 DHF patients. P-value of 
0.001 showed a significant difference in their mean values as well 
[Table 1].
ALT and AST tests were repeated on the 5th day of DF and 
the critical phase of DHF patients. Among 518 ALT samples, 215 
DF and 303 DHF patients were there. In that population, mean 
ALT values for DF and DHF were 74 and 126.3, respectively, 
resulting in a significant difference in the 0.048 P value. Similarly, 
513 samples were collected from 214 DF to 299 DHF patients for 
AST. There means value for DF was 98.7 and for DHF, it was187.4. 
A P = 0.036 suggested that a significant difference in their 
means too. For emphasis, we noticed that there were significant 
differences between AST and ALT levels among DF and DHF 
patients, not only on day 5 of the critical phase but also during the 
acute febrile phase [Table 1].
ROC curve was drawn for AST and ALT to gain predictive 
values for DHF at the acute febrile phase. Area under the ROC 
curve for AST was 0.7, but for ALT, it was 0.6 [Figure 1]. However, 
the area under the ROC curve was 0.70 which indicates that AST 
at the acute febrile phase is a good indicator of leaking tendency. 
According to the coordinate points of the curve at an AST value 
of 59.5, leaking can be predicted with a sensitivity of 72% and a 
specificity of 60% [Table 2].
dI s c u s s I o n
Prediction of DHF patients among dengue patients during the 
acute febrile phase was the purpose of this study. Changes of 
serum levels of transaminase were used as the variables. Elevation 
of transaminase levels during dengue infection is due to the 
involvement of liver, heart, myocytes, etc. It is a common condition 
for both acute febrile phase and day 5 of the critical phase, but the 
issue is how transaminase levels are more elevated in DHF patients 
than DF patients even during the acute febrile phase. That means 
some hidden pathology is progressing in DHF patients compared 
to DF patients suggesting that patients who are going to have 
DHF are pre-decided in the acute febrile phase. Although the 
exact pathology behind this has not been clearly identified, the 
exaggeration of dysregulated host immune response and direct 
virus invasion in DHF patients may be the reasons for this.
During the critical phase, the reason for the elevation of ALT 
and AST in DHF patients than DF patients is not clearly understood. 
This cannot be purely due to hypoxia on target organs because 
all DHF patients were stable in the critical phase, as none of them 
developed circulatory compromisation. This means that the 
pathology which had taken place during the acute phase continues.
AST is more accurate than ALT in this context as in both 
phases, the rise of AST is more prominent than ALT. The result of 
59.5 AST value in the acute febrile phase can be used as a predictor 
of DHF, although this is not significantly higher than its normal 
range (normal range of AST = 10–40). Reason behind that could 
be the involvement of other organs such as heart, muscles, brain, 
kidney, and red blood cells other than the liver.[16,17,37-38] It has been 
Table 1: Distribution of AST and ALT values
Phase of illness DH/DHF n Mean 
(U/L)
SD SEM P value
Acute phase
ALT DF 134 57.7 53.2 4.6 0.003
DHF 220 86.3 81.6 5.5
AST DF 134 66.5 59.6 5.1 0.001
DHF 217 108.9 102.1 6.9
Critical/day >5
ALT DF 215 74 82.7 5.6 0.048
DHF 303 126.3 268.1 15.4
AST DF 214 98.7 108.6 7.4 0.036
DHF 299 187.4 439.2 25.4
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, 
DF: Dengue fever, DHF: Dengue hemorrhagic fever, SD: Standard deviation, 
SEM: Standard error of the mean
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reported that transaminase started to rise during the acute febrile 
phase and AST peaked on the 6th day of the illness while ALT 
peaked on the 7th day of the illness. It may also be a reason for AST 
to elevate more than ALT in our study since AST was more toward 
its peak than ALT at the time we collected blood samples for AST 
and ALT (blood samples for AST and ALT during the acute febrile 
phase and day 5 of critical phase and most patients progressed 
to the critical phase around day 5 were collected). Similarly, in a 
study which was carried out in Singapore, it was also observed that 
elevated liver transaminase levels were associated with DHF, but 
threshold values were unable to be received to differentiate DF 
from DHF.[17] Going beyond this study done in Taiwan, it was found 
that both ALT and AST were independent predictors of DHF.[16,38]
co n c lu s I o n
AST remains more sensitive and specific than ALT, reflecting 
that AST value of 59.5 at the acute febrile phase can be used to 
predict DHF. However, patients who have significantly elevated 
transaminase levels at the acute febrile phase have a higher 
tendency to develop DHF and they need more medical attention 
than others to overcome the DHF and its complications.
Limitations
Several short comes have been identified in this study. We could 
not assess the AST and ALT levels at regular intervals in our patients 
rather than waiting for clinical evidence. We assume that elevated 
AST and ALT were only from the liver and other causes which could 
elevate the AST and ALT were excluded only through history. The 
current study was restricted to only hospitalized patients and 
conducted in a single hospital. Identification of dengue virus 
serotype and correlation of liver involvement was not carried out 
in this study. A strong generalization of the findings may be limited 
without a multi-center study or a meta-analysis of similar data 
obtained from two or more regions.
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Table 2: Coordinates of the curve
Test result 
variable
Positive if greater 
than or equal to
Sensitivity Specificity
AST 59.5 0.72 0.6
AST: Aspartate aminotransferase
Figure 1: Discriminatory performance of aspartate aminotransferase 
and alanine aminotransferase
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